Status:
COMPLETED
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Pfizer
Conditions:
Ischemia Reperfusion Injury
Cardiovascular Disease
Eligibility:
MALE
18-50 years
Phase:
PHASE4
Brief Summary
To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.
Detailed Description
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) have been found to reduce cardiovascular events. This protective effect has been traditionally explained by lowering ...
Eligibility Criteria
Inclusion
- Male
- Age 18-50 years
- Informed consent
- Physical able to perform ischemic exercise
Exclusion
- History of any cardiovascular disease
- Hypertension (in supine position: systole \> 140 mmHg, diastole \> 90 mmHg)
- Diabetes mellitus (fasting glucose \> 7.0 mmol/L or random glucose \> 11.0 mmol/L)
- Hyperlipidaemia (fasting total cholesterol \> 5.5 mmol/l)
- Alanine-Amino-Transferase (ALAT) \>90 U/L
- Creatinine Kinase (CK) \>440 U/L
- Drug or alcohol abuse
- Concommitant chronic use of medication
- Administration of radioactivity in research setting during the last 5 years
- Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00441597
Start Date
February 1 2007
End Date
March 1 2009
Last Update
March 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500 HB